ArticleFrontiers in pediatrics2025
Bioinformatic identification of COLEC12 as a diagnostic biomarker and risk factor in pediatric FSGS.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In children, focal and segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) have a similar appearance on electron microscopy, making them indistinguishable in clinical diagnosis. Here, we conducted genomic screening to identify a biomarker for the differential diagnosis and assess its clinical implications in pediatric FSGS. Methods: In the study, cohorts from public databases were analyzed through informatics analysis. First, molecular characteristics were analyzed using Gene Set Enrichment Analysis (GSEA) and Gene Ontology (GO) annotation, and Xcell was used to evaluate the infiltration of immune cells. Next, diagnostic and differentially diagnostic values of candidate biomarkers were studied using Receiver Operating Characteristic (ROC) curve analysis. Simultaneously, the clinical significance of the biomarker was analyzed in pediatric FSGS. Results: Compared to the healthy population, There were 27 genes significantly up-regulated and 129 genes significantly down-regulated in FSGS patients, which related to immune response and cell apoptosis. In FSGS, the T helper (Th) effector memory cell and macrophage M2 cell were significantly highly infiltrated. Meanwhile, regulatory T cells (Tregs) and plasma B cells showed a significant decrease. COLEC12 is the most different gene between FSGS and MCD, and had high value in the diagnosis and differential diagnosis of FSGS. In pediatric FSGS, COLEC12 expression is associated with poor prognosis. Conclusion: FSGS is intricately linked with immune responses. COLEC12 is a risk factor for FSGS in children and a candidate marker for FSGS diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.